ERBB2 and ovarian carcinoma: For instance, Gaborit et al. demonstrated that trastuzumab significantly blocks EGFR-HER2 heterodimerization in the SKOV-3 HER2-positive ovarian cancer cell line using a Fluorescence Resonance Energy Transfer (FRET)-based method [25].